TY - JOUR
T1 - Association of Vaccination with the Persistence of Post-COVID Symptoms
AU - Wisnivesky, Juan P.
AU - Govindarajulu, Usha
AU - Bagiella, Emilia
AU - Goswami, Ruchir
AU - Kale, Minal
AU - Campbell, Kirk N.
AU - Meliambro, Kristin
AU - Chen, Zijian
AU - Aberg, Judith A.
AU - Lin, Jenny J.
N1 - Funding Information:
Dr. Wisnivesky received consulting honorarium from Atea, Sanofi, PPD, and Banook and grants from Sanofi, Arnold Consulting, and Regeneron. Dr. Aberg reports grants from Atea, Emergent Biosolutions, Frontier Technologies, Gilead Sciences, Glaxo Smith Kline, Janssen, Merck, Pfizer, Regeneron, and Viiv Healthcare and consulting honorarium from Glaxo Smith Kline and Merck. The other authors report no conflicts of interest.
Publisher Copyright:
© 2022, The Author(s) under exclusive licence to Society of General Internal Medicine.
PY - 2022/5
Y1 - 2022/5
N2 - Background: Patients who have had COVID-19 often report persistent symptoms after resolution of their acute illness. Recent reports suggest that vaccination may be associated with improvement in post-acute symptoms. We used data from a prospective cohort to assess differences in post-acute sequelae of COVID (PASC) among vaccinated vs. unvaccinated patients. Methods: We used data from a cohort of COVID-19 patients enrolled into a prospective registry established at a tertiary care health system in New York City. Participants underwent a baseline evaluation before COVID-19 vaccines were available and were followed 6 months later. We compared unadjusted and propensity score–adjusted baseline to 6-month change for several PASC–related symptoms and measures: anosmia, respiratory (cough, dyspnea, phlegm, wheezing), depression, anxiety, post-traumatic stress disorder (PTSD; COVID-19-related and other trauma), and quality-of-life domains among participants who received vs. those who did not receive COVID-19 vaccination. Results: The study included 453 COVID-19 patients with PASC, of which 324 (72%) were vaccinated between the baseline and 6-month visit. Unadjusted analyses did not show significant differences in the baseline to 6-month change in anosmia, respiratory symptoms, depression, anxiety, PTSD, or quality of life (p > 0.05 for all comparisons) among vaccinated vs. unvaccinated patients. Similar results were found in propensity-adjusted comparisons and in secondary analyses based on the number of vaccine doses received. Conclusions: Our findings suggest that COVID vaccination is not associated with improvement in PASC. Additional studies are needed to better understand the mechanisms underlying PASC and to develop effective treatments.
AB - Background: Patients who have had COVID-19 often report persistent symptoms after resolution of their acute illness. Recent reports suggest that vaccination may be associated with improvement in post-acute symptoms. We used data from a prospective cohort to assess differences in post-acute sequelae of COVID (PASC) among vaccinated vs. unvaccinated patients. Methods: We used data from a cohort of COVID-19 patients enrolled into a prospective registry established at a tertiary care health system in New York City. Participants underwent a baseline evaluation before COVID-19 vaccines were available and were followed 6 months later. We compared unadjusted and propensity score–adjusted baseline to 6-month change for several PASC–related symptoms and measures: anosmia, respiratory (cough, dyspnea, phlegm, wheezing), depression, anxiety, post-traumatic stress disorder (PTSD; COVID-19-related and other trauma), and quality-of-life domains among participants who received vs. those who did not receive COVID-19 vaccination. Results: The study included 453 COVID-19 patients with PASC, of which 324 (72%) were vaccinated between the baseline and 6-month visit. Unadjusted analyses did not show significant differences in the baseline to 6-month change in anosmia, respiratory symptoms, depression, anxiety, PTSD, or quality of life (p > 0.05 for all comparisons) among vaccinated vs. unvaccinated patients. Similar results were found in propensity-adjusted comparisons and in secondary analyses based on the number of vaccine doses received. Conclusions: Our findings suggest that COVID vaccination is not associated with improvement in PASC. Additional studies are needed to better understand the mechanisms underlying PASC and to develop effective treatments.
KW - COVID vaccination
KW - long COVID
KW - post-acute sequelae of COVID
KW - symptoms
UR - http://www.scopus.com/inward/record.url?scp=85126039707&partnerID=8YFLogxK
U2 - 10.1007/s11606-022-07465-w
DO - 10.1007/s11606-022-07465-w
M3 - Article
C2 - 35266128
AN - SCOPUS:85126039707
SN - 0884-8734
VL - 37
SP - 1748
EP - 1753
JO - Journal of General Internal Medicine
JF - Journal of General Internal Medicine
IS - 7
ER -